These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19539340)

  • 1. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
    Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.
    Quakkelaar ED; Bunnik EM; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Schuitemaker H
    Virology; 2007 Jul; 363(2):447-53. PubMed ID: 17355886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
    Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
    J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
    Bunnik EM; Quakkelaar ED; van Nuenen AC; Boeser-Nunnink B; Schuitemaker H
    J Virol; 2007 Jan; 81(2):525-31. PubMed ID: 17079299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
    Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
    AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
    Zhou N; Fan L; Ho HT; Nowicka-Sans B; Sun Y; Zhu Y; Hu Y; McAuliffe B; Rose B; Fang H; Wang T; Kadow J; Krystal M; Alexander L; Colonno R; Lin PF
    Virology; 2010 Jul; 402(2):256-61. PubMed ID: 20400170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12.
    Armbruster C; Stiegler GM; Vcelar BA; Jäger W; Köller U; Jilch R; Ammann CG; Pruenster M; Stoiber H; Katinger HW
    J Antimicrob Chemother; 2004 Nov; 54(5):915-20. PubMed ID: 15456731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
    Ringe R; Thakar M; Bhattacharya J
    Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
    Gray ES; Meyers T; Gray G; Montefiori DC; Morris L
    PLoS Med; 2006 Jul; 3(7):e255. PubMed ID: 16834457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
    Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
    AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.